Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease

Summary

The objective was to describe the indices of platelet aggregation and activation in a large cohort of diabetic patients with coronary artery disease (CAD). Recently, a number of observations have indicated that patients with diabetes mellitus (DM) exhibit persistent platelet activation, and low response after antiplatelet therapy, although no randomized data exist. We sought to define the baseline platelet biomarkers, and the patterns of response to aspirin and clopidogrel therapy in DM versus non-diabetic patients. Secondary post-hoc analyses were made of platelet activity biomarkers in the dataset which consisted of patients with documented CAD (n=822), including those with DM (n=257). Patients with DM exhibited higher baseline platelet activity by adenosine diphosphate (ADP)- (p=0.0002), and collagen-induced (p=0.03) aggregometry; Ultegra- (p=0.0001), and PFA-100 (p=0.02) analyzers; and expression of platelet/endothelial cell adhesion molecule-1 (PECAM-1) (p=0.01), glycoprotein (GP) IIb/IIIa antigen (p=0.001), and activity (p=0.02), vitronectin receptor (p=0.03), P selectin (p=0.02), and intact epitope of PAR-1 thrombin receptor (p=0.02). Antiplatelet response after clopidogrel in diabetics was impaired when compared with non-diabetics. In conclusion, diabetic patients exhibit high pretreatment platelet activity, and do not respond well to the available antiplatelet regimens when compared with similar patients without DM. The clinical implications of these findings are unknown but are potentially important. Considering worsened outcomes in this high-risk population, clinical trials in DM are urgently needed in order to define the optimal degree of platelet inhibition and suitability for more aggressive antiplatelet regimens.

Keywords

Diabetes mellitus - platelet pharmacology - antiplatelet agents

• References

• 1 The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88-136.
• 2 American Diabetes Association. Standard of medical care in diabetes. Diabetes Care 2007; 30 SI, 4-41.
• 3 American Diabetes Association. Diabetes: 1991 Vital Statistics. Alexandria, VA: American Diabetes Association.;
• 4 Kimura M, Ishizawa M, Miura A. et al. Platelet protein kinase C isoform content in type 2 diabetes complicated with retinopathy and nephropathy. Platelets 2001; 12: 138-143.
• 5 Simpson AJ, Booth NA, Moore NR. et al. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study. Acta Diabetol 1999; 36: 155-158.
• 6 Harding SA, Sommerfield AJ, Sarma J. et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004; 176: 321-325.
• 7 Vinik AI, Erbas T, Park TS. et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485.
• 8 Kajita K, Ishizuka T, Miura A. et al. Increased platelet aggregation in diabetic patients with microangio-pathy despite good glycemic control. Platelets 2001; 12: 343-351.
• 9 Hansen HH, Joensen AM, Riahi S. et al. Short and long-term outcome in diabetic patients with acute myo cardial infarction in the invasive era. Scand Cardiovasc J 2007; 41: 19-24.
• 10 AACE Diabetes Guidelines. Endocr Pract. 2002; 08 (Suppl. 01) 54.
• 11 Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hemat 1994; 31: 229-239.
• 12 Mammen EF, Comp PC, Gosselin R. et al. PFA -100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
• 13 Smith JW, Steinhubl SR, Lincoff AM. et al. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 1999; 99: 620-625.
• 14 Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann NY Acad Sci 1993; 677: 293-308.
• 15 Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P – selectin? Thromb Haemost 1999; 81: 314-316.
• 16 American Diabetes Association. Standards of medical care in diabetes–2006. Diabetes Care 2006; 29: S4-S42.
• 17 ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report. J Am Med Assoc 1992; 268: 1292-1300.
• 18 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
• 19 Angiolillo DJ, Shoemaker SB, Desai B. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-716.
• 20 Kleiman NS, Lincoff AM, Kereiakes DJ. et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multi-center trial. EPILOG Investigators. Circulation 1998; 97: 1912-1920.
• 21 Winocour PD. Platelets, vascular disease, and diabetes mellitus. Can J Physiol Pharmacol 1994; 72: 295-303.
• 22 Gosk-Bierska I, Adamiec R, Doskocz W. et al. Chronic peripheral arterial occlusive disease, platelet glycoproteins GPIIb-IIIa and GP Ib-IX, plasma von Willebrand factor and plasma fibrinogen concentrations in patients with type 2 diabetes mellitus. Pol Arch Med Wewn 2000; 103: 139-145.
• 23 Hishinuma T, Tsukamoto H, Suzuki K. et al. Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 191-196.
• 24 Konieczkowski M, Skrinska VA. Increased synthesis of thromboxane A(2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 133-138.
• 25 Yazbek N, Bapat A, Kleiman N. Platelet abnormalities in diabetes mellitus. Coron Artery Dis 2003; 14: 365-371.
• 26 Serebruany V, Malinin A, Pokov A. et al. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?. Thromb Res 2007; 119: 175-181.
• 27 Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007; 49: 631-642.
• 28 Serebruany VL, Malinin AI, Pokov AN. et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial. Am Heart J 2007; 155: 93 e1–7.
• 29 Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55: 202-208.
• 30 Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 07: 223-227.
• 31 Moreno PR, Murcia AM, Palacios IF. et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102: 2180-2184.
• 32 Virmani R, Burke AP, Kolodgie F. Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can J Cardiol 2006; 22 (Suppl B) 81B-84B.
• 33 Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004; 164: 2106-2110.
• 34 Kelly RV, Hsu A, Topol E. et al. The influence of body mass index on outcomes and the benefit of anti-platelet therapy following percutaneous coronary intervention. J Invasive Cardiol 2006; 18: 115-119.
• 35 Wiviott SD, Braunwald E, McCabe CH. et al. and the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 36 Angiolillo DJ, Bernardo E, Sabaté M. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547.
• 37 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97: 38-43.
• 38 Geisler T, Anders N, Paterok M. et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-374.
• 39 Serebruany VL, Oshrine BR, Malinin AI. et al. Noncompliance in clinical trials. Am Heart J 2005; 150: 882-886.